Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab biosimilar - EirGenix

Next Previous
Drug Profile

Pertuzumab biosimilar - EirGenix

Alternative Names: EG-1206A; Perjeta

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EirGenix
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 25 Mar 2025 EirGenix plans a phase III trial for HER2-positive Hormone Receptor-negative Early Breast Cancer (Combination therapy, Neoadjuvant therapy) (IV, Infusion), in May 2025 (NCT06884254)
  • 22 Nov 2023 EirGenix plans a phase III trial for HER2 positive Breast cancer in unknown location
  • 02 May 2023 Pertuzumab biosimilar - EirGenix is available for licensing as of 08 May 2023. https://www.eirgenix.com/

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top